WHO Tackles Submission Of Insufficient Or False Data By Pharma
This article was originally published in SRA
The World Health Organization has developed what it claims is the first comprehensive guidance document on data integrity that should help regulatory authorities and inspectors identify instances of pharmaceutical companies submitting insufficient or false data1.
You may also be interested in...
The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date.
Pharmaceutical Inspection Cooperation Scheme member inspectorates are trying out the most comprehensive manufacturing data integrity guidance yet developed. Issued amid a flurry of guidance from various authorities, it could play a key role in harmonizing regulatory approaches.
The EMA's guidance on data integrity expectations focuses on good manufacturing practice requirements and offers advice on minimizing risks at all stages of the data lifecycle in pharmaceutical quality systems.